Roivant Sciences Ltd. (ROIV) Price Targets: What Do They Mean?

As of Thursday close, Roivant Sciences Ltd.’s (NASDAQ:ROIV) stock was down -$0.01, moving down -0.35 percent to $2.81. The average number of shares traded per day over the past five days has been 583,400 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.99 fall in that time frame. In the last twenty days, the average volume was 423,445, while in the previous 50 days, it was 470,692.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Since last month, ROIV stock retreated -29.40%. Shares of the company fell to $2.52 on 05/12/22, the lowest level in the past month. Since the beginning of this year, ROIV’s stock price has dropped by -72.12% or -$7.27, and marked a new high 1 time. However, the stock has declined by -83.23% since its 52-week high.

Roivant Sciences Ltd. (ROIV) last reported insider trading activity 18 days ago on Apr 25. Dexcel Pharma Technologies Ltd, the 10% Owner of the company, purchased of 8,600 shares for $3.91 on Apr 25. It resulted in a $33,635 investment by the insider. Gline Matthew sold 8,509 shares at an average price of $3.84 on Apr 25. The insider now owns 1,404,448 shares following the transaction. On Apr 25, President & COO Venker Eric sold 5,107 shares at $3.84 apiece. The transaction was valued at $19,611.

Financial Health

In the three months ended September 29, Roivant Sciences Ltd.’s quick ratio stood at 14.20, while its current ratio was 14.20, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 0.11, and the total debt-to-equity ratio was 0.11. On the profitability front, the trailing twelve-month gross margin is 85.30% percent.

In Roivant Sciences Ltd.’s quarter-end financial report for September 29, it reported total debt of $204.04 million. ROIV’s revenue rose 100.0% to $13.99 million during the quarter, while net income inched up to $24.34 million. While analysts expected Roivant Sciences Ltd. to report -$0.22 quarterly earnings, the actual figure was -$0.32 per share, beating the consensus estimate by -45.50%.

Technical Picture

This quick technical analysis looks at Roivant Sciences Ltd.’s (ROIV) price momentum. With a historical volatility rate of 75.31%, the RSI 9-day stood at 20.15% on 12 May.

With respect to its five-day moving average, the current Roivant Sciences Ltd. price is down by -26.05% percent or -$0.99. At present, ROIV shares trade -31.96% below its 20-day simple moving average and -74.34% percent below its 100-day simple moving average. However, the stock is currently trading approximately -55.18% below its SMA50.

Stochastic coefficient K was 7.72% and Stochastic coefficient D was 5.81%, while ATR was 0.33. Given the Stochastic reading of 17.16% for the 14-day period, the RSI (14) reading has been calculated as 24.92%. As of today, the MACD Oscillator reading stands at -0.54, while the 14-day reading stands at -0.69.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles